Drug Discovery
By
How Did Novartis Navigate 2025 and What’s Ahead for 2026?
In 2025, Novartis demonstrated resilience and strategic focus, balancing strong performance in its core franchises with investments in…
How Did AbbVie’s 2025 Deals Shape Its Year, and What Do They Signal for Growth in 2026?
NORTH CHICAGO, IL — As 2025 concludes, AbbVie Inc. reflects on a year of strategic dealmaking that complements…
Did AbbVie Successfully Manage 2025 Headwinds, and Are Rinvoq and Skyrizi Poised to Reach $31B+ Sales by 2027?
NORTH CHICAGO, ILLINOIS — As 2025 comes to a close, AbbVie reflects on a year marked by strong…
Is Lilly Shaping Its Post-Blockbuster Future Through Verve, Superluminal, and AI-Driven Partnerships in 2025?
In 2025, Eli Lilly and Company approached dealmaking from a position of strength. With blockbuster brands driving growth…
Can Johnson & Johnson’s 2025 Product Momentum and Portfolio Execution Sustain Leadership Across Oncology, Immunology, and MedTech Into 2026 and Beyond?
Global | January 2026 — Johnson & Johnson continued to reinforce its position as one of the world’s…
Can Gilead’s 2025 Approvals and Targeted Launches Reinforce Leadership in HIV, Oncology, and Liver Disease Into 2026 and Beyond?
Global | January 2026 — Gilead Sciences, Inc. strengthened its innovation-led growth profile in 2025 through a focused…
